Publications by authors named "L P Bechmann"

Article Synopsis
  • - Post-viral symptoms have gained attention during the COVID-19 pandemic, with increased reports after SARS-CoV-2 infection compared to other viruses like influenza.
  • - A study analyzing data from 573,791 individuals found that COVID-19 patients experienced post-viral symptoms and tissue damage more frequently than those with influenza or other controls, though symptom persistence was similar for both infections.
  • - The findings highlight the significant burden of post-viral symptoms from COVID-19, emphasizing the need for further research into effective treatments as the disease remains a serious health concern.
View Article and Find Full Text PDF

Purpose: Evidence on the incidence and persistence of post-acute sequelae of COVID-19 (PASC) among children and adolescents is still limited.

Methods: In this retrospective cohort study, 59,339 children and adolescents with laboratory-confirmed COVID-19 in 2020 and 170,940 matched controls were followed until 2021-09-30 using German routine healthcare data. Incidence rate differences (ΔIR) and ratios (IRR) of 96 potential PASC were estimated using Poisson regression.

View Article and Find Full Text PDF

Introduction: Immunocompromised patients are at an increased risk of severe legionella infections. We present the results of an outbreak investigation initiated following a fatal case of hospital-acquired legionellosis linked to contaminated water from a toilet-flushing cistern. Additionally, we provide experimental data on the growth of Legionella spp.

View Article and Find Full Text PDF

Background: Nonalcoholic fatty liver disease (NAFLD) is a disease characterized by lipid accumulation within hepatocytes, ranging from simple steatosis to steatohepatitis, in the absence of secondary causes of hepatic fat accumulation. Although air pollution (AP) has been associated with several conditions related to NAFLD (e.g.

View Article and Find Full Text PDF

Background And Aims: Sodium glucose co-transporter 2 (SGLT2)-inhibitors were developed as glucose-lowering drugs. Surprisingly, SGLT2-inhibitors also reduced risk of cardiovascular disease. The impact of SGLT2-inhibitors on lipids and lipoproteins is unclear, but an effect might contribute to the observed lower cardiovascular risk.

View Article and Find Full Text PDF